After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

"For patients in high-deductible health plans or who have cost sharing arrangements the increases will hit them." Find out if ...

Shareholders request Human Rights Due Diligence to determine whether pharma companies do everything they can to increase drug ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small molecule oral signal transducer and activator of ...

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to ...

Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...

Major moves in the pharmaceutical industry include Ownership Matters recommending support for the Chemist Warehouse-Sigma Healthcare merger, J&J's potential bid for Intra-Cellular Therapies, and ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN – Research Report), Rhythm ...